Most Read Articles
Elaine Soliven, 18 Sep 2020
Adding mepolizumab to standard of care treatment significantly reduces nasal polyp size and obstruction in adults with chronic rhinosinusitis with nasal polyps (CRSwNP), according to the SYNAPSE* study presented at ERS 2020.
Rachel Soon, 28 Aug 2020
MOH Director-General Tan Sri Dato' Seri Dr Noor Hisham Abdullah speaks about NHMS 2019 and pharmacists' roles in combating NCDs among Malaysians.
Rachel Soon, 12 Dec 2018

MIMS Pharmacist speaks to Cpt. Manvikram Singh Gill, military pharmacist with the Royal Medical and Dental Corps (RMDC) of the Malaysian Armed Forces (MAF),about his work at the Rohingya refugee camp in Cox's Bazar, Bangladesh.

Audrey Abella, 21 Sep 2020
A single-inhaler triple therapy containing FF/UMEC/VI* may be a good option for COPD** patients who remain symptomatic despite dual bronchodilation with an ICS/LABA or a LAMA/LABA*** and at risk for exacerbations, according to data presented at ERS 2020.

AF patients not on anticoagulation therapy at higher risk of death after TAVR

25 Nov 2020

Individuals with atrial fibrillation (AF), diabetes, or low albumin levels are at increased risk of mortality following transcatheter aortic valve replacement (TAVR), with AF patients who are not anticoagulated being at greatest risk of dying, reveals a study.

“Efforts to identify AF and consider anticoagulation should be emphasized,” the investigators said.

Overall, 176 patients who underwent TAVR at a single centre were included in this analysis. Logistic regression was used to examine the factors associated with pacemaker implantation within 30 days, while those correlating with mortality were evaluated using Kaplan-Meier and Cox regression analyses.

Of the patients (mean age, 80±8.5 years), 69 had AF and 39 received anticoagulation. Twenty-five patients underwent a pacemaker implantation within 30 days after TAVR. Forty-nine patients succumbed to death over a follow-up of 566±496 days.

Multivariable analysis revealed that the right bundle branch block remained significant (odds ratio, 4.212; p=0.012) for pacemaker implant within 30 days. In addition, mortality was associated independently with AF (hazard ratio [HR], 3.905; p=0.001), albumin level (HR, 0.316; p=0.034), and diabetes (HR, 2.323; p=0.027), but not with pacemaker implant within 30 days.

In a stratified Kaplan-Meier analysis, AF patients who received anticoagulation therapy had better survival than those who did not receive treatment (p=0.0001).

“Patients that undergo TAVR are at risk for complete heart block requiring pacemaker implant,” the investigators said. “Additionally, other arrhythmias, specifically AF, are common in this population.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elaine Soliven, 18 Sep 2020
Adding mepolizumab to standard of care treatment significantly reduces nasal polyp size and obstruction in adults with chronic rhinosinusitis with nasal polyps (CRSwNP), according to the SYNAPSE* study presented at ERS 2020.
Rachel Soon, 28 Aug 2020
MOH Director-General Tan Sri Dato' Seri Dr Noor Hisham Abdullah speaks about NHMS 2019 and pharmacists' roles in combating NCDs among Malaysians.
Rachel Soon, 12 Dec 2018

MIMS Pharmacist speaks to Cpt. Manvikram Singh Gill, military pharmacist with the Royal Medical and Dental Corps (RMDC) of the Malaysian Armed Forces (MAF),about his work at the Rohingya refugee camp in Cox's Bazar, Bangladesh.

Audrey Abella, 21 Sep 2020
A single-inhaler triple therapy containing FF/UMEC/VI* may be a good option for COPD** patients who remain symptomatic despite dual bronchodilation with an ICS/LABA or a LAMA/LABA*** and at risk for exacerbations, according to data presented at ERS 2020.